
After 14 years at Lundbeck, Chief Financial Officer Anders Götzsche will depart the Danish pharmaceutical firm no later than May 2022. He is set to join another, as of yet undisclosed, unlisted Danish company.
Deborah Dunsire, CEO at Lundbeck, expects to be able to announce where Götzsche is headed soon. However, it is safe to say that it isn't to one of Lundbeck's competitors, she tells MedWatch.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.